Shares of Advaxis Inc. (NASDAQ:ADXS) shot up 5.9% on Wednesday . The stock traded as high as $8.91 and last traded at $8.56, with a volume of 1,161,444 shares traded. The stock had previously closed at $8.08.

Several brokerages recently weighed in on ADXS. FBR & Co restated an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a research report on Thursday. HC Wainwright restated a “buy” rating on shares of Advaxis in a research report on Wednesday, June 29th. Finally, Jefferies Group restated a “buy” rating on shares of Advaxis in a research report on Friday, June 10th. Six investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $24.80.

The stock has a 50-day moving average price of $8.48 and a 200 day moving average price of $8.19. The stock’s market capitalization is $294.00 million.

In other news, Director Thomas J. Mckearn sold 4,100 shares of Advaxis stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the completion of the transaction, the director now directly owns 82,120 shares in the company, valued at $611,794. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Daniel O’connor sold 8,237 shares of Advaxis stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $7.51, for a total value of $61,859.87. Following the completion of the transaction, the chief executive officer now owns 316,661 shares of the company’s stock, valued at $2,378,124.11. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Advaxis stock. Oxford Asset Management acquired a new stake in shares of Advaxis Inc. (NASDAQ:ADXS) during the fourth quarter, Holdings Channel reports. The firm acquired 146,282 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Oxford Asset Management owned approximately 0.43% of Advaxis at the end of the most recent quarter.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.